Can a new injection tame hereditary swelling attacks?
NCT ID NCT06415448
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This program provides access to an investigational drug called donidalorsen for people with hereditary angioedema (HAE), a genetic condition that causes sudden, painful swelling in various body parts. The drug is given as a monthly or every-other-month injection under the skin. It is available to patients who have completed a prior long-term study of donidalorsen, aiming to see if continued use can help manage their condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- donidalorsen
- What this could lead to
- If successful, this program could provide a new treatment option for people with hereditary angioedema, potentially reducing the frequency and severity of swelling attacks.
- What could go wrong
- This is an expanded access program, not a formal trial, so it provides limited safety and efficacy data. The drug may not work for everyone, and there are risks of side effects, including injection site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral option may offer relief for hereditary angioedema attacks
- Could a simple pill shield HAE patients from Procedure-Triggered attacks?
- Teens with rare swelling disorder get new drug tested
- New drug shows promise for controlling rare swelling disorder
- New drug navenibart aims to tame hereditary swelling attacks
- Gene therapy aims to stop painful swelling attacks in hereditary angioedema